retatrutide creator - “Triple G” Unapproved weight loss drug retatrutide
Description
These drugs can also produce side effects that may spur changes in eating habits, which can lead to safety risks or worse health outcomes if not appropriately managed
Retatrutide at 12 mg produced ~67% GI events vs semaglutide 2.4 mg at ~74%
View published research Literature / Peer-Reviewed Retatrutide Published Research Retatrutide (LY3437943) is a triple agonist peptide targeting GIP, GLP-1, and glucagon receptors simultaneously
Mol Vis
How Do I Get Ozempic for $25 a Month
A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis
